Role of sustained antigen release from nanoparticle vaccines in shaping the T cell memory phenotype

Biomaterials

Volumn 33, Issue 19, 2012, Pages 4957-4964

  Demento, Stacey L ^a   Cui, Weiguo ^b   Criscione, Jason M ^a   Stern, Eric ^a   Tulipan, Jacob ^a   Kaech, Susan M ^b   Fahmy, Tarek M ^a  

^a Yale University   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Liposome; Memory T cells; Nanoparticle; Persistence; PLGA; Vaccine

Indexed keywords

ANTIBODY TITERS; ANTIGEN DELIVERY; CELLULAR RESPONSE; HIGHER FREQUENCIES; IMMUNE RESPONSE; INTRACELLULAR BACTERIA; MEMORY T CELLS; PERSISTENCE; PLGA; POLY-LACTIDE-CO-GLYCOLIDE; T CELLS; VACCINE DELIVERY;

ANTIGENS; BACTERIA; ENZYME ACTIVITY; IMMUNIZATION; LIPOSOMES; NANOPARTICLES; PHOSPHOLIPIDS;

VACCINES;

ALUMINUM POTASSIUM SULFATE; ANTIGEN; BACTERIAL ANTIGEN; LIPOSOME; NANOPARTICLE; POLYGLACTIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY TITER; ARTICLE; BACTERIUM; CELLULAR IMMUNITY; EFFECTOR CELL; IMMUNE RESPONSE; IMMUNIZATION; KINETICS; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; T LYMPHOCYTE; VACCINATION;

ANIMALS; ANTIGENS; FEMALE; LACTIC ACID; LIPOSOMES; MICE; MICE, INBRED BALB C; NANOPARTICLES; POLYGLYCOLIC ACID; T-LYMPHOCYTES; VACCINES;

BACTERIA (MICROORGANISMS); MUS;

EID: 84859838781     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2012.03.041     Document Type: Article

References (49)

1. Peek L.J., Middaugh C.R., Berkland C. Nanotechnology in vaccine delivery. Adv Drug Deliv Rev 2008, 60:915-928.
2. Look M., Bandyopadhyay A., Blum J.S., Fahmy T.M. Application of nanotechnologies for improved immune response against infectious diseases in the developing world. Adv Drug Deliv Rev 2010, 62:378-393.
3. Moon J.J., Suh H., Polhemus M.E., Ockenhouse C.F., Yadava A., Irvine D.J. Antigen-Displaying lipid-Enveloped PLGA nanoparticles as delivery agents for a Plasmodium vivax Malaria vaccine. PLoS One 2012, 7:e31472.
4. Demento S.L., Eisenbarth S.C., Foellmer H.G., Platt C., Caplan M.J., Mark Saltzman W., et al. Inflammasome-activating nanoparticles as modular systems for optimizing vaccine efficacy. Vaccine 2009, 27:3013-3021.
5. Powell T.J., Palath N., DeRome M.E., Tang J., Jacobs A., Boyd J.G. Synthetic nanoparticle vaccines produced by layer-by-layer assembly of artificial biofilms induce potent protective T-cell and antibody responses in vivo. Vaccine 2011, 29:558-569.
6. Krishnamachari Y., Geary S.M., Lemke C.D., Salem A.K. Nanoparticle delivery systems in cancer vaccines. Pharm Res 2011, 28:215-236.
7. Adair B.M. Nanoparticle vaccines against respiratory viruses. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2009, 1:405-414.
8. Reddy S.T., van der Vlies A.J., Simeoni E., Angeli V., Randolph G.J., O'Neil C.P., et al. Exploiting lymphatic transport and complement activation in nanoparticle vaccines. Nat Biotechnol 2007, 25:1159-1164.
9. Petersen L.K., Ramer-Tait A.E., Broderick S.R., Kong C.S., Ulery B.D., Rajan K., et al. Activation of innate immune responses in a pathogen-mimicking manner by amphiphilic polyanhydride nanoparticle adjuvants. Biomaterials 2011, 32:6815-6822.
10. Zhang Z., Tongchusak S., Mizukami Y., Kang Y.J., Ioji T., Touma M., et al. Induction of anti-tumor cytotoxic T cell responses through PLGA-nanoparticle mediated antigen delivery. Biomaterials 2011, 32:3666-3678.
11. Ali J., Ali M., Baboota S., Sahani J.K., Ramassamy C., Dao L., et al. Potential of nanoparticulate drug delivery systems by intranasal administration. Curr Pharm Des 2010, 16:1644-1653.
12. Chadwick S., Kriegel C., Amiji M. Nanotechnology solutions for mucosal immunization. Adv Drug Deliv Rev 2010, 62:394-407.
13. de la Fuente M., Csaba N., Garcia-Fuentes M., Alonso M.J. Nanoparticles as protein and gene carriers to mucosal surfaces. Nanomedicine (Lond) 2008, 3:845-857.
14. Cruz L.J., Tacken P.J., Fokkink R., Figdor C.G. The influence of PEG chain length and targeting moiety on antibody-mediated delivery of nanoparticle vaccines to human dendritic cells. Biomaterials 2011, 32:6791-6803.
15. Yu D., Wang A., Huang H., Chen Y. PEG-PBLG nanoparticle-mediated HSV-TK/GCV gene therapy for oral squamous cell carcinoma. Nanomedicine (Lond) 2008, 3:813-821.
16. Wattendorf U., Merkle H.P. PEGylation as a tool for the biomedical engineering of surface modified microparticles. J Pharm Sci 2008, 97:4655-4669.
17. Bandyopadhyay A., Fine R.L., Demento S., Bockenstedt L.K., Fahmy T.M. The impact of nanoparticle ligand density on dendritic-cell targeted vaccines. Biomaterials 2011, 32:3094-3105.
18. Fahmy T.M., Demento S.L., Caplan M.J., Mellman I., Saltzman W.M. Design opportunities for actively targeted nanoparticle vaccines. Nanomedicine (Lond) 2008, 3:343-355.
19. O'Hagan D.T., Valiante N.M. Recent advances in the discovery and delivery of vaccine adjuvants. Nat Rev Drug Discov 2003, 2:727-735.
20. Kirby D.J., Rosenkrands I., Agger E.M., Andersen P., Coombes A.G., Perrie Y. Liposomes act as stronger sub-unit vaccine adjuvants when compared to microspheres. J Drug Target 2008, 16:543-554.
21. Faisal S.M., Yan W., McDonough S.P., Chang Y.F. Leptospira immunoglobulin-like protein A variable region (LigAvar) incorporated in liposomes and PLGA microspheres produces a robust immune response correlating to protective immunity. Vaccine 2009, 27:378-387.
22. Mohanan D., Slutter B., Henriksen-Lacey M., Jiskoot W., Bouwstra J.A., Perrie Y., et al. Administration routes affect the quality of immune responses: a cross-sectional evaluation of particulate antigen-delivery systems. J Control Release 2010, 147:342-349.
23. Allison A.G., Gregoriadis G. Liposomes as immunological adjuvants. Nature 1974, 252:252.
24. Altman A., Dixon F.J. Immunomodifiers in vaccines. Adv Vet Sci Comp Med 1989, 33:301-343.
25. O'Hagan D.T., Rahman D., McGee J.P., Jeffery H., Davies M.C., Williams P., et al. Biodegradable microparticles as controlled release antigen delivery systems. Immunology 1991, 73:239-242.
26. Dudani R., Chapdelaine Y., Faassen Hv., Smith D.K., Shen H., Krishnan L., et al. Multiple mechanisms compensate to enhance tumor-protective CD8(+) T cell response in the long-term despite poor CD8(+) T cell priming initially: comparison between an acute versus a chronic intracellular bacterium expressing a model antigen. J Immunol 2002, 168:5737-5745.
27. Demento S.L., Bonafe N., Cui W., Kaech S.M., Caplan M.J., Fikrig E., et al. TLR9-targeted biodegradable nanoparticles as immunization vectors protect against West Nile encephalitis. J Immunol 2010, 185:2989-2997.
28. Marrack P., McKee A.S., Munks M.W. Towards an understanding of the adjuvant action of aluminium. Nat Rev Immunol 2009, 9:287-293.
29. Demento S.L., Siefert A.L., Bandyopadhyay A., Sharp F.A., Fahmy T.M. Pathogen-associated molecular patterns on biomaterials: a paradigm for engineering new vaccines. Trends Biotechnol 2011, 29:294-306.
30. Kaech S.M., Wherry E.J. Heterogeneity and cell-fate decisions in effector and memory CD8+ T cell differentiation during viral infection. Immunity 2007, 27:393-405.
31. Sallusto F., Lanzavecchia A., Araki K., Ahmed R. From vaccines to memory and back. Immunity 2010, 33:451-463.
32. Cui W., Kaech S.M. Generation of effector CD8+ T cells and their conversion to memory T cells. Immunol Rev 2010, 236:151-166.
33. Germain R.N. Vaccines and the future of human immunology. Immunity 2010, 33:441-450.
34. Pulendran B., Ahmed R. Translating innate immunity into immunological memory: implications for vaccine development. Cell 2006, 124:849-863.
35. Masopust D., Ha S.J., Vezys V., Ahmed R. Stimulation history dictates memory CD8 T cell phenotype: implications for prime-boost vaccination. J Immunol 2006, 177:831-839.
36. Pulendran B., Ahmed R. Immunological mechanisms of vaccination. Nat Immunol 2011, 131:509-517.
37. Ochsenbein A.F., Karrer U., Klenerman P., Althage A., Ciurea A., Shen H., et al. A comparison of T cell memory against the same antigen induced by virus versus intracellular bacteria. Proc Natl Acad Sci U S A 1999, 96:9293-9298.
38. Kalia V., Sarkar S., Subramaniam S., Haining W.N., Smith K.A., Ahmed R. Prolonged interleukin-2Ralpha expression on virus-specific CD8+ T cells favors terminal-effector differentiation in vivo. Immunity 2010, 32:91-103.
39. Badovinac V.P., Messingham K.A., Jabbari A., Haring J.S., Harty J.T. Accelerated CD8+ T-cell memory and prime-boost response after dendritic-cell vaccination. Nat Med 2005, 11:748-756.
40. Cui W., Joshi N.S., Jiang A., Kaech S.M. Effects of Signal 3 during CD8 T cell priming: Bystander production of IL-12 enhances effector T cell expansion but promotes terminal differentiation. Vaccine 2009, 27:2177-2187.
41. Joshi N.S., Cui W., Chandele A., Lee H.K., Urso D.R., Hagman J., et al. Inflammation directs memory precursor and short-lived effector CD8(+) T cell fates via the graded expression of T-bet transcription factor. Immunity 2007, 27:281-295.
42. Masopust D., Vezys V., Marzo A.L., Lefrancois L. Preferential localization of effector memory cells in nonlymphoid tissue. Science 2001, 291:2413-2417.
43. Sallusto F., Lenig D., Forster R., Lipp M., Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 1999, 401:708-712.
44. Krishnan L., Dicaire C.J., Patel G.B., Sprott G.D. Archaeosome vaccine adjuvants induce strong humoral, cell-mediated, and memory responses: comparison to conventional liposomes and alum. Infect Immun 2000, 68:54-63.
45. Jeong J.M., Chung Y.C., Hwang J.H. Enhanced adjuvantic property of polymerized liposome as compared to a phospholipid liposome. J Biotechnol 2002, 94:255-263.
46. Moon J.J., Suh H., Bershteyn A., Stephan M.T., Liu H., Huang B., et al. Interbilayer-crosslinked multilamellar vesicles as synthetic vaccines for potent humoral and cellular immune responses. Nat Mater 2011, 10:243-251.
47. Cohen S., Bernstein H., Hewes C., Chow M., Langer R. The pharmacokinetics of, and humoral responses to, antigen delivered by microencapsulated liposomes. Proc Natl Acad Sci U S A 1991, 88:10440-10444.
48. Richards R.L., Rao M., Vancott T.C., Matyas G.R., Birx D.L., Alving C.R. Liposome-stabilized oil-in-water emulsions as adjuvants: increased emulsion stability promotes induction of cytotoxic T lymphocytes against an HIV envelope antigen. Immunol Cell Biol 2004, 82:531-538.
49. Harding C.V., Collins D.S., Kanagawa O., Unanue E.R. Liposome-encapsulated antigens engender lysosomal processing for class II MHC presentation and cytosolic processing for class I presentation. J Immunol 1991, 147:2860-2863.